<DOC>
	<DOC>NCT02079909</DOC>
	<brief_summary>The primary objective is to evaluate the efficacy of T-817MA as measured by ADAS-cog and ADCS-CGIC. The secondary objectives are: - To evaluate the safety and tolerability of T-817MA measured by clinical safety laboratories, physical examinations, ECGs and solicitation of adverse events. - To evaluate the efficacy of T-817MA as measured by ADCS-ADL, FAQ, Neuropsychiatric Inventory (NPI) and Mini-mental State Examination (MMSE).</brief_summary>
	<brief_title>Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Male or female (postmenopausal or surgically sterile) Patients with Mild to moderate Alzheimer's disease who are receiving donepezil (Aricept®) or rivastigmine transdermal system (Exelon® Patch), . Memantine (Namenda®) is allowed only when prescribed in combination with donepezil or rivastigmine transdermal system. Age 55 to 85 inclusive Patients must be living in the community Patients must have an eligible informant or study partner (caregiver) Patients and eligible informant or study partner (caregiver) must be able to read and understand English. Informed consent obtained from both the patient and the caregiver Patients with clinically significant cardiac, hepatic or renal impairment Patient have a dementia not of the Alzheimer's type etc (According to the protocol) Patients who are taking any drug other than donepezil or rivastigmine transdermal system for Alzheimer's disease, including olal rivastigmine (Exelon®), galantamine (Razadyne®)</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Alzheimer's Disease</keyword>
	<keyword>Alzheimer's</keyword>
</DOC>